Thinking of joining a study?

Register your interest

NCT05711199 | Recruiting | Brown Adipose Tissue


Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis
Sponsor:

University Hospital, Basel, Switzerland

Brief Summary:

The aim of this study is to evaluate the efficacy of glyceroltrinitrate (Nitroderm® TTS) to activate and expand human BAT as compared to mild cold exposure.

Condition or disease

Brown Adipose Tissue

Intervention/treatment

Glyceroltrinitrat

Phase

Early Phase 1

Detailed Description:

The activation of brown adipose tissue in response to glyceroltrinitrate as compared to cold exposure will be studied in an open-label, cross-over trial in healthy volunteers with random sequence of the two study periods (treatment and control) seperated by a washout period of 7 days. In the treatment phase all participants will receive Nitroderm® TTS (glyceroltrinitrate) for a total of 15 days. For better tolerability, it will be will started with a lower dose of 5mg/24h (Nitroderm® TTS) the first 5 days and after that a change to Nitroderm® TTS 10mg/24h for another 10 days will be done. Each transdermal patch will be applied for 12 hours per day (overnight) to avoid development of nitrate tolerance. Energy expenditure will be measured by indirect calorimetry before and after a mild cold exposure by placing a medical cooling system around their midsection. Additionally brown adipose tissue activity will determined by 18F-FDG-PET/CT 30 min after injection of 75 MBq of 18F-FDG. To analyse changes in BAT and muscle which are caused by glyceroltrinitrate as compared with cold stimulus, a tissue biopsie of supraclavicular BAT and skeletal muscle (musculus vastus lateralis) will be performed. To measure changes in glucose tolerance and triglyceride levels a mixed meal test will be performed during control and treatment phase respectively. Additionally, a indirect calorimetry will be conducted before and after mixed meal test to assess diet-induced thermogenesis, i.e. the increase in REE due to ingestion of nutrients In control phase the same examinations will be performed, but without glyceroltrinitrat.}}

Study Type : Interventional
Estimated Enrollment : 25 participants
Masking : None (Open Label)
Primary Purpose : Basic Science
Official Title : Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis
Actual Study Start Date : March 1, 2023
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : March 31, 2025
Arm Intervention/treatment

Experimental: normal weight

Treatment phase administration of glyceroltrinitrate (Nitroderm TTS) for 15 days. measurement of energy expenditure before and after cold exposure performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle) measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test. Control phase: measurement of energy expenditure before and after cold exposure performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle) measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test.

Drug: Glyceroltrinitrat

Experimental: overweight

Treatment phase administration of glyceroltrinitrate (Nitroderm TTS) for 15 days. measurement of energy expenditure before and after cold exposure performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle) measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test. Control phase: measurement of energy expenditure before and after cold exposure performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle) measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test.

Drug: Glyceroltrinitrat

Ages Eligible for Study: 18 Years to 40 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Accepts Healthy Volunteers
Criteria
Inclusion Criteria
  • BMI 18.5 to 25 kg/m2 or 30 to 35kg/m2
  • Able to give informed consent as documented by signature
  • Age 18 to 40 years
Exclusion Criteria
  • Contraindications to glyceroltrinitrate, e.g. known hypersensitivity or allergy
  • Concomitant medication: Non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, diuretics, antihypertensives, fibrates or statins, metformin, PDE-5-inhibitors
  • Clinically significant concomitant disease states (e.g. renal failure, hepatic dysfunction, cardiovascular disease, diabetes mellitus)
  • Hypersensitivity to cold (e.g. Raynaud Syndrome)
  • Orthostatic hypotension: systolic blood pressure decreases min. 20mmHg or diastolic blood pressure decreases min 10mmHg within 3-5min after standing up (Schellong Test at screening visit)
  • History of orthostatic syncope or pre-syncope
  • Blood pressure values below 100 mmHg systolic and 60 mmHg diastolic
  • Allergy to local anesthetic
  • Hypothyroidism without sufficient substitution
  • Hyperthyroidism
  • Claustrophobia
  • Smoker / habitual tobacco use
  • Habitual excessive alcohol use
  • Weight change of >5% within 3 months prior to inclusion
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Enrolment into another study using ionizing radiation within the previous 12 months
  • Pregnant or lactating women
  • Lab parameters
  • Hb below lower reference limit
  • Glycated Hemoglobin (HbA1c): above 6.0%
  • Random plasma glucose >11 mM

Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis

Location Details


Please Choose a site



Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Recruiting

Switzerland, BS

University Hospital Basel, Department of Endocrinology

Basel, BS, Switzerland, 4031

Loading...